Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Orforglipron - Eli Lilly and Company

Next Previous
Drug Profile

Orforglipron - Eli Lilly and Company

Alternative Names: GLP-1 receptor NPA - Eli Lilly and Company; Glucagon like peptide 1 receptor NPA - Eli Lilly and Company; LY-3502970; OWL 833

Latest Information Update: 24 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Eli Lilly and Company
  • Class Antihyperglycaemics; Antihypertensives; Fluorinated hydrocarbons; Imidazoles; Indazoles; Indoles; Ketones; Obesity therapies; Oxadiazoles; Pyrazoles; Pyridines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypertension; Obesity; Sleep apnoea syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 17 Sep 2025 Efficacy and adverse event data from the phase III ACHIEVE-3 trial in Type 2 diabetes mellitus released by Eli Lilly and Company
  • 16 Sep 2025 Eli Lilly and Company plans to submit regulatory application for Obesity to global regulatory agencies by the early 2026
  • 16 Sep 2025 Efficacy and adverse event data from the phase III ATTAIN-1 trial released by Eli Lily and Company

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top